SCHEMBL15035331

SCHEMBL15035331

Cc1ccc(-c2cc3cnc(Nc4ccc(NC5CCCNC5)cc4)nc3n(C3C(=O)c4ccccc4SC3(C)C)c2=O)c(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 5/20 0.40
RIPK2 O43353 2/20 0.40
NOD2 Q9HC29 2/20 0.40
FGFR1 P11362 4/20 0.38
MAPK14 Q16539 2/20 0.38
ABL1 P00519 1/20 0.38
EGFR P00533 1/20 0.38
PDGFRB P09619 1/20 0.38
SRC P12931 1/20 0.38
PDGFRA P16234 1/20 0.38
CDK2 P24941 5/20 0.37
PAK1 Q13153 3/20 0.37
PAK2 Q13177 2/20 0.37
CCNT1 O60563 1/20 0.37
CCNK O75909 1/20 0.37
CCNE1 P24864 1/20 0.37
CDK7 P50613 1/20 0.37
CDK9 P50750 1/20 0.37
CCNH P51946 1/20 0.37
MNAT1 P51948 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15035407 0.87 TNK2 (0.42) TNK2RIPK2NOD2FGFR1MAPK14
SCHEMBL15035341 0.84 RIPK2 (0.41) TNK2RIPK2NOD2FGFR1MAPK14
SCHEMBL15035291 0.83 RIPK2 (0.42) TNK2RIPK2NOD2FGFR1MAPK14
SCHEMBL15035297 0.80 CDK4 (0.39) FGFR1EGFRCDK2CDK4CCNA2
SCHEMBL15035445 0.78 RIPK2 (0.43) TNK2RIPK2NOD2FGFR1MAPK14
SCHEMBL15035548 0.77 RIPK2 (0.43) TNK2RIPK2NOD2FGFR1MAPK14
SCHEMBL15035395 0.75 CDK4 (0.37) TNK2FGFR1MAPK14ABL1PDGFRB
SCHEMBL15041600 0.74 CDK4 (0.39) FGFR1CDK2CCNE1CDK4CCNA2
SCHEMBL15035255 0.74 PAK1 (0.42) TNK2RIPK2NOD2PAK1PAK2
SCHEMBL15034773 0.74 TNK2 (0.44) TNK2RIPK2NOD2MAPK14PAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 TNK2 7/4885RIPK2 971/4885NOD2 4628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.